

## **DONATION AGREEMENT LEAD GRANT**

between

CSL Behring NV  
Bedrijvenlaan 11  
2800 Mechelen  
Belgium

- hereinafter referred to as „CSL Behring“ -

and

Danmarks Bløderforening  
Blekinge Boulevard 2  
2630 Taastrup  
Denmark

- hereinafter referred to as „Beneficiary “ -

CSL Behring and Beneficiary will hereinafter also be referred to individually as a “Party” and collectively as “Parties”.

### **1. SCOPE OF THE AGREEMENT**

- 1.1. CSL Behring Local Empowerment for Advocacy Development (LEAD) Grants are community-based grants. These grants are intended to help local patient organizations achieve their advocacy objectives. CSL Behring awards European LEAD Grants to organizations that submit proposals demonstrating that financial assistance would help them address important advocacy issues and initiatives. Subject of this Donation Agreement („Agreement“) is the financial support of the Beneficiary as outlined in the Donation Purposes in Attachment 1.
- 1.2. The Beneficiary is obliged to return the Donation, if the above-mentioned Donation Purposes are not fulfilled.

### **2. OBLIGATIONS OF THE BENEFICIARY**

- 2.1. Beneficiary undertakes to use the Donation exclusively for tasks and activities in connection with its Donation Purposes set forth in Attachment 1. Beneficiary undertakes not to use the Donation for any private purposes.
- 2.2. Beneficiary agrees that it will comply with the national law as well as rules, regulations, codes of conduct, professional standards, guidelines and directives. Beneficiary shall refrain from any and all behavior that shall be regarded as illegal commercial practice

concerning pharmaceuticals or any action that illegally incites the healthcare professionals to do favour or ensure advantage to CSL Behring. In signing this Agreement, Beneficiary warrants that receiving account is subject to full and sole authority of Beneficiary.

- 2.3. Beneficiary agrees to issue a signed receipt for contributions paid under this Agreement as soon as contributions paid pursuant to Section 3 of this Agreement are credited to the account of Beneficiary.
- 2.4. If requested by CSL Behring, Beneficiary reports to CSL Behring regarding the progress achieved in fulfilling the Donation Purposes, including evidence of utilization of the Donation for the Donation Purposes. The report shall be in writing.

### **3. OBLIGATIONS OF CSL BEHRING**

- 3.1. CSL Behring agrees to support the Donation Purposes set forth in Attachment 1 with a financial contribution in the amount of 10.000,00 € (in words: ten thousand Euros).
- 3.2. CSL Behring shall transfer the above-mentioned amount within thirty (30) days after the Agreement has been signed by the Parties hereto.
- 3.3. Financial contributions due for payment shall be transferred directly to the following account of Beneficiary:

Account holder: Sydbank: 7040-1106847

IBAN: DK9370400001106847

SWIFT: SYBKDK22

Purpose: European LEAD GRANT CSL Behring 2025

- 3.4. CSL Behring ensures that the Donation meets the applicable legal requirements and guidelines.

### **4. DISCLOSURE, PUBLICATION**

- 4.1. Beneficiary shall make publicly available information on financial and/or non-financial support and funding received by CSL Behring. In particular, Beneficiary shall ensure that CSL Behring's support is always clearly acknowledged and apparent from the outset. CSL Behring shall be entitled to present itself as a supporting partner of Beneficiary and to make publicly available information relating to the provided Donation, particularly as regards the total amount of the provided funds, the entity to which the funds were provided and the purpose for which these funds were provided.
- 4.2. Beneficiary acknowledges that CSL Behring may, in accordance with EFPIA Code on Disclosure of Transfers of Value and applicable national disclosure codes (hereinafter "Disclosure Code"), collect, process and publish in the public domain certain information pertaining to any transfers of value from CSL Behring to Beneficiary, including the identification of Beneficiary and the amount and character of the transfer of value. For the purposes of the disclosure, information that is subject to the obligations under the Disclosure Code shall be exempt from any duties of confidentiality.

### **5. TERM**

This Agreement enters into force as of the day it is duly signed by the Parties and ends with the payment of the Donation, but at the latest on 30 June 2026.

6. MISCELLANEOUS

- 6.1. In consideration of anti-corruption legislation, Parties limit their cooperation under this Agreement exclusively to the principles of admissible cooperation. The Parties therefore acknowledge that with performance of obligations under this Agreement no influence shall be exerted in order to ensure that relationships between the pharmaceutical industry and Foundation take place in an ethical and transparent manner. The Parties confirm that the Agreement does not influence sales transactions and that no such expectations in this respect exist.
- 6.2. This Agreement contains the entire agreement for each Party. It may not be changed orally but only by an agreement in writing signed by the Party against whom enforcement of any such change, waiver, modification, construction, extension or discharge is sought.
- 6.3. All of the provisions of this Agreement are distinct and severable, and if any provisions should, for any reason, be held to be invalid or unenforceable, then the valid and enforceable provisions hereof shall continue in full force and effect.

24 June 2025 | 08:07:28 CEST  
Belgium, \_\_\_\_\_

Copenhagen 23 juni 2025 | 22:36:02 CEST  
\_\_\_\_\_, \_\_\_\_\_

**Donor**  
CSL Behring L.L.C.

**Beneficiary**  
Danmarks Bløderforening

Signed by:  
  
DE438609EC214EB...

Name: Joelle Khraiche

Title: Director International Patient Advocacy & Public Affairs

Signed by:  
  
46A0A742616D4F7...

Name: Karen Binger Holm

Title: CEO

24 June 2025 | 03:20:17 EDT  
Belgium, \_\_\_\_\_

Signed by:  
  
F16AB85AA81F4E7...

Name: Irene De Cara Torres

Title: Head International PAGA

## Attachment 1

Danmarks Bløderforening  
Blekinge Boulevard 2  
2630 Taastrup  
Tlf. 3314 5505  
[www.bloderforeningen.dk](http://www.bloderforeningen.dk)



### LEAD Grant Application 2025

Organisation: The Danish Haemophilia Society

President: Jacob Bech Andersen

Phone number: +4533145505

Email: [dbf@bloderforeningen.dk](mailto:dbf@bloderforeningen.dk)

Address: Blekinge Boulevard 2, DK-2630 Taastrup

Name of main contact: Karen Binger Holm, CEO

As the first country in Europe the Danish Medicines Council has announced in June 2024 that gene therapy is recommended as treatment for patients with hemophilia B (<https://medicinraadet.dk/nyheder/2024/medicinraadet-anbefaler-genterapien-hemgenix-efter-ny-effektbaseret-prisaftale>). Gene therapy is a new and totally different way of treating hemophilia B. As Dr. Peter Kampmann sum up the benefits: "The benefit of gene therapy is the freedom and identity change that hemophiliacs experience by being free of regular intravenous transfusions." (<https://ugeskriftet.dk/videnskab/genterapi-haemofili-b>). Accepting new treatment technologies is however not necessarily easy for Danish patients with haemophilia. Due to the tragic history of HIV and Aids, there is a caution towards new medicine. This caution may not be rational, but is, however, very real for many members of the Danish Haemophilia Society. To change this perception, strengthening the patients' health literacies is vital.

The Danish Haemophilia Society will develop digital educational material about gene therapy for hemophilia for our members to understand what gene therapy is, how it works, and what the benefits, the risks and the consequences are. Illustration of the patient journey will be a part of the project. In February the first Danish patient with haemophilia B was treated with gene therapy at the Royal Hospital in Copenhagen (<https://haematologisktidsskrift.dk/sygdomme/haemofili/1536-forste-danske-patient-med-haemofili-b-behandlet-med-hemgenix.html>). According to the Danish Medicines Council 15 Danish patients in total are candidates for this specific treatment (<https://filer.medicinraadet.dk/media/kmtd204t/medicinradets-anbefaling-vedr-etranacogene-dezaparvovec-til-haemofili-b-vers-2-0-x.pdf>).

The aim of this educational project is to strengthen the health literacy among people with haemophilia in Denmark for them to make sound decisions regarding their current and future treatment, such as gene therapy.

The project will be carried out in May/June 2025 by communication officer Anne Mette Christensen. The project has three phases: 1) Gathering information including interviews with a patient in gene therapy and candidates and health experts, 2) Producing educational material, including personal story, expert interview, and graphic visualization of the patient journey, 3) Publishing at the homepage (<https://www.bloderforeningen.dk/>), and communication through digital newsletter and SoMe.

Budget: 8.843 Euro/65.958 DKK